Actively Recruiting
Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes: Microcephalic Osteodysplastic Primordial Dwarfism Types I and III, Roifman and Lowry-Wood Syndromes
Led by Hospices Civils de Lyon · Updated on 2024-10-09
45
Participants Needed
6
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating rare developmental disorders linked to mutations in the RNU4ATAC and RTTN genes. These disorders include Taybi-Linder Syndrome, Roifman Syndrome, Lowry-Wood Syndrome, and Microcephalic Osteodysplastic Primordial Dwarfism Types I and III. These conditions cause growth delays before and after birth, small head size, skeletal problems, intellectual disability, retinal issues, and immune system deficiencies. The study aims to understand how defects in minor RNA splicing caused by these gene mutations affect cell functions and contribute to these syndromes. The study involves collecting biological samples such as blood and skin biopsies from patients with bi-allelic mutations in RNU4ATAC or RTTN, their parents with mono-allelic mutations, and fetuses with these mutations after miscarriage or medical abortion. These samples will help create induced pluripotent stem cell lines and analyze gene expression, RNA splicing, cell functions, and tissue structure. The study does not involve drug treatments but focuses on laboratory and cellular analyses. Participants will provide blood and possibly skin samples, while parents of fetuses with mutations may consent to tissue biopsies after pregnancy termination. Researchers will study the cellular consequences of RNU4ATAC mutations over five years, including minor splicing anomalies and neuronal differentiation issues. The research includes transcriptomic, biochemical, and cellular assessments to better understand the diseases' mechanisms and does not involve randomization or blinding.
CONDITIONS
Brief Title
Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with Taybi Linder Syndrome, Roifman Syndrome, Lowry-Wood Syndrome, or related pathologies
- Male or female of any age
- Presence of bi-allelic mutations in RNU4ATAC or RTTN genes
- Written consent from parents or legal guardians
- Affiliation to a Social Security scheme
- Healthy parents of patients with mono-allelic RNU4ATAC mutations, age 18 or older
- Written consent from the participant
- Parents who have had a medical termination or miscarriage with fetal bi-allelic mutations in RNU4ATAC or RTTN
- Written parental consent
- Affiliation to a Social Security scheme
You will not qualify if you...
- Participation in another research study with an active exclusion period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants provide biological samples including blood and skin biopsies for study analysis. Fetal samples are collected in the autopsy room after medical termination or miscarriage.
Visits as needed for sample collection
Trial Site Locations
Total: 6 locations
1
Centre de référence des anomalies du développement et syndromes malformatifs du Sud-Ouest Occitanie Réunion, CHU de Bordeaux-GH Pellegrin
Bordeaux, France, 33000
Not Yet Recruiting
2
Centre de référence anomalies du développement de Lyon, Hôpital Femme Mère Enfant
Bron, France, 69500
Actively Recruiting
3
Centre de référence des anomalies du développement et syndromes malformatifs de l'Est, CHU de DIJON
Dijon, France, 9000
Not Yet Recruiting
4
Centre de référence des anomalies du développement et syndromes malformatifs de l'inter région Nord-Ouest, Hôpital J de Flandre
Lille, France, 59000
Not Yet Recruiting
5
Unité Fonctionelle d'embryo-fœtopathologie, Hôpital Necker-Enfants Malades
Paris, France, 75743
Not Yet Recruiting
6
Centre de référence des anomalies du développement et syndromes malformatifs de l'Ouest, Hôpital Sud
Rennes, France, 35000
Not Yet Recruiting
Research Team
S
Sylvie MAZOYER, Dr
P
Patrick EDERY, Pr
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
5
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here